Lexicon Pharmaceuticals Inc.'s diabetes drug sotagliflozin achieved a sustained benefit in A1C, a measure that estimates average blood sugar levels, over a 52-week period in adult patients with type 1 diabetes who were on insulin therapy.

According to additional data from a phase 3 trial, both 200- and 400-milligram doses of the investigational dual SGLT1 and SGLT2 inhibitor also showed statistically significant results compared to placebo for secondary goals, including reduced weight and blood pressure.

Systolic blood pressure in the subset of type 1 diabetic patients in the study with baseline hypertension was also statistically significantly reduced with the 400-milligram dose compared with placebo.

Previously, both doses of sotagliflozin achieved the primary goal in the study, showing statistically significant reductions in A1C at 24 weeks.